NASDAQ:APLMW Apollomics (APLMW) Stock Price, News & Analysis $0.03 0.00 (-4.17%) As of 08/8/2025 03:34 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock About Apollomics Stock (NASDAQ:APLMW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Apollomics alerts:Sign Up Key Stats Today's Range$0.02▼$0.0350-Day Range$0.01▼$0.0452-Week Range$0.01▼$0.05Volume22,905 shsAverage Volume84,408 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Apollomics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies in the field of immuno-oncology. The company’s research focuses on novel small molecules designed to modulate key pathways involved in tumor growth and immune evasion. Apollomics leverages a combination of proprietary chemistry and translational biology to advance its pipeline candidates from preclinical studies into human trials. The company’s lead programs include APG-115, an MDM2 inhibitor aimed at restoring p53 tumor suppressor activity, and APG-1252, a BCL-2/BCL-XL inhibitor prodrug engineered to induce apoptosis in cancer cells resistant to conventional therapies. Additional assets, such as APG-2449 (a multi-kinase inhibitor targeting FGFR and MET), further reflect Apollomics’ strategy of addressing multiple tumor types through targeted mechanisms. These candidates are being evaluated in Phase 1/2 trials across the United States and China, with several combination studies planned to explore synergistic approaches with established immunotherapies. Apollomics operates from its corporate headquarters in Fremont, California, with research and development facilities in Shanghai. The company’s leadership team combines drug development expertise from both U.S. and Chinese oncology markets, supporting a global footprint in clinical operations and regulatory interactions. Through strategic collaborations and a cross-border infrastructure, Apollomics aims to accelerate the availability of its therapies to patients worldwide.AI Generated. May Contain Errors. Read More Receive APLMW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLMW Stock News HeadlinesApollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business ProgressApril 3, 2025 | globenewswire.comApollomics and LaunXP Announce Development and Commercialization Agreement for VebreltinibMarch 31, 2025 | globenewswire.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant. | The Oxford Club (Ad)Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid LeukemiaDecember 20, 2024 | globenewswire.comApollomics Regains Compliance with Nasdaq's Minimum Bid Price RequirementDecember 10, 2024 | globenewswire.comApollomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comApollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressAugust 14, 2024 | globenewswire.comApollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA TrialAugust 13, 2024 | globenewswire.comSee More Headlines APLMW Stock Analysis - Frequently Asked Questions How have APLMW shares performed this year? Apollomics' stock was trading at $0.0092 at the start of the year. Since then, APLMW shares have increased by 175.0% and is now trading at $0.0253. How do I buy shares of Apollomics? Shares of APLMW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:APLMW CIK1944885 Webwww.apollomicsinc.com Phone650-209-4055FaxN/AEmployees59Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:APLMW) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.